TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10638374

Group type: EXPERIMENTAL
Intervention: High-intensity dynamic resistance training (WT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 9480650

Group type: EXPERIMENTAL
Intervention: Pefloxacin (800 mg daily for 7-10 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine antibiotics (benzylpenicillin, ampicillin, erythromycin)
Number of subjects: 30
Study: 8438774

Group type: EXPERIMENTAL
Intervention: Lactose maldigesters and intolerant group
Number of subjects: 164

Group type: COMPARATOR
Intervention: Low-lactose milk and milk containing lactose
Number of subjects: 164
Study: 3679106

Group type: EXPERIMENTAL
Intervention: Supportive art therapy group (10 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 30288918

Group type: EXPERIMENTAL
Intervention: Intervention arm (PSA tests and digital rectal examinations)
Number of subjects: 76383

Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 76383

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 76383

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 76383
Study: 27824737

Group type: EXPERIMENTAL
Intervention: 10% povidone‐iodine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine gluconate
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 122
Study: 25880054

Group type: EXPERIMENTAL
Intervention: 4 g/day omega‐3 fatty acids plus 400 IU/day vitamin E (OE)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 4 g/day omega‐3 fatty acids plus vitamin E placebo (OP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Both omega‐3 fatty acid and vitamin E placebos (PP)
Number of subjects: 67
Study: 23907314

Group type: EXPERIMENTAL
Intervention: Subfascial approach
Number of subjects: 86

Group type: COMPARATOR
Intervention: Subplatysmal approach
Number of subjects: 86
Study: 21497319

Group type: EXPERIMENTAL
Intervention: 10-week supervised hip flexor stretching program (twice-daily, supervised twice weekly)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Shoulder abductor stretching program (control group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 10-week supervised hip flexor stretching program
Number of subjects: 74
Study: 19850207

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg daily for 6 months, increased to 50 mg daily from 6 to 12 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 44
Study: 17438512

Group type: EXPERIMENTAL
Intervention: Low-dose local vaginal estrogen therapy
Number of subjects: 0
Study: 15197196

Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Number of subjects: 184

Group type: COMPARATOR
Intervention: No PET
Number of subjects: 184
Study: 12374247

Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9825751

Group type: EXPERIMENTAL
Intervention: 0.5 mg triple helical collagen type II
Number of subjects: 92

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 92
Study: 7813220

Group type: EXPERIMENTAL
Intervention: 200 mg dose of doxycycline
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 2805141

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study: 1209742

Group type: EXPERIMENTAL
Intervention: Topical ampicillin (0.5-1 g into the wound before closure)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (no ampicillin)
Number of subjects: 420
Study: 7352522

Group type: EXPERIMENTAL
Intervention: Oxygen administration
Number of subjects: 32

Group type: COMPARATOR
Intervention: Room air administration
Number of subjects: 32
Study: 30145738

Group type: EXPERIMENTAL
Intervention: Smart After-Care (smartphone application and pedometer)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Exercise education only
Number of subjects: 356
Study: 28424185

Group type: EXPERIMENTAL
Intervention: 3.9 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) per day for 6 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (4.2 g oleate per day for 6 months)
Number of subjects: 21
Study: 25635359

Group type: EXPERIMENTAL
Intervention: Antegrade reaming
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Retrograde reaming
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 94
Study: 24095609

Group type: EXPERIMENTAL
Intervention: Exemestane + Ovarian Function Suppression (OFS)
Number of subjects: 5738

Group type: EXPERIMENTAL
Intervention: Tamoxifen + Ovarian Function Suppression (OFS)
Number of subjects: 5738

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 5738
Study: 21883635

Group type: EXPERIMENTAL
Intervention: Procedural sedation with etomidate as the sole agent
Number of subjects: 42

Group type: COMPARATOR
Intervention: US-guided interscalene nerve block
Number of subjects: 42
Study: 19217008

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling of the lower second molar (L2M) root surface
Number of subjects: 43

Group type: COMPARATOR
Intervention: Manual scaling and root planing
Number of subjects: 43
Study: 17582705

Group type: EXPERIMENTAL
Intervention: Randomized controlled HIV/HCV prevention trial
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Baseline assessments
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Contextual factors
Number of subjects: 3285
Study: 14962146

Group type: EXPERIMENTAL
Intervention: Structured education of nurses and nursing home residents and provision of free hip protectors
Number of subjects: 511

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Intervention group predictors: use of walking aid
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Intervention group predictors: no urinary incontinence
Number of subjects: 511

Group type: COMPARATOR
Intervention: Usual care predictors: nursing staff per 10 residents
Number of subjects: 511

Group type: COMPARATOR
Intervention: Usual care predictors: high degree of disablement
Number of subjects: 511

Group type: COMPARATOR
Intervention: Usual care predictors: strong fear of falling
Number of subjects: 511

Group type: COMPARATOR
Intervention: Nursing home cluster
Number of subjects: 511
Study: 12078790

Group type: EXPERIMENTAL
Intervention: Autologous priming
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (no autologous priming)
Number of subjects: 104
Study: 9445321

Group type: EXPERIMENTAL
Intervention: Ebselen (150 mg BID for 2 weeks)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 7614505

Group type: EXPERIMENTAL
Intervention: cilazapril (CLZ) 1‐2.5 mg once daily (n = 221)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: captopril (CPT) 25‐50 mg three times daily (n = 108)
Number of subjects: 443

Group type: COMPARATOR
Intervention: placebo (PLA) (n = 114)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: cilazapril (CLZ)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: captopril (CPT)
Number of subjects: 443
Study: 2515753

Group type: EXPERIMENTAL
Intervention: Once‐daily lithium carbonate (Priadal)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Twice‐daily lithium citrate (Litarex)
Number of subjects: 25
Study: 983179

Group type: EXPERIMENTAL
Intervention: RMP (Rifampicin)
Number of subjects: 220

Group type: COMPARATOR
Intervention: EMB (Ethambutol)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: EMB added to chemotherapy regimen
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: RMP added to EMB regimen
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: RMP (Rifampicin) in 220 chronic patients
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: EMB and another combination in 54 new cases
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: RMP added to treatment in 20 new cases
Number of subjects: 220

Group type: COMPARATOR
Intervention: RMP vs EMB
Number of subjects: 220
Study: 30727996

Group type: EXPERIMENTAL
Intervention: Integrated mental health care program (intervention group)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 349
Study: 29311704

Group type: EXPERIMENTAL
Intervention: Kinkeliba (Combretum micranthum) 190 mg × 2/day
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Bissap (Hibiscus sabdariffa) 320 mg × 2/day
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ramipril 5 mg/day
Number of subjects: 125
Study: 26356750

Group type: EXPERIMENTAL
Intervention: Keraring implantation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Keraring insertion followed by TE‐CXL 1 month later
Number of subjects: 29
Study: 23418955

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHG) for 10 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group for 10 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Post-training systolic BP reactivity to SST and IHGT
Number of subjects: 24
Study: 25551914

Group type: EXPERIMENTAL
Intervention: New protocol of arterial puncture with fine needle (paf)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional arterial puncture methods
Number of subjects: 0
Study: 19967620

Group type: EXPERIMENTAL
Intervention: BIS monitoring (n = 46)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (n = 44)
Number of subjects: 90
Study: 16965419

Group type: EXPERIMENTAL
Intervention: PASI
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LS-PGA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PGA
Number of subjects: 16
Study: 15181054

Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg/d)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Metformin (1000 mg/d)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 82
Study: 12085979

Group type: EXPERIMENTAL
Intervention: Spironolactone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9850359

Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 micrograms day-1 (delivered as four actuations of 50 micrograms twice daily)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 micrograms day-1 (delivered as two actuations of 100 micrograms twice daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: HFA-placebo
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: HFA-BDP (both dosing regimens)
Number of subjects: 256
Study: 7866911

Group type: EXPERIMENTAL
Intervention: Experimental diet (150 mg calcium and 1600 mg phosphorus daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Baseline serum intact parathyroid hormone (PTH) concentration
Number of subjects: 30
Study: 2670633

Group type: EXPERIMENTAL
Intervention: Erythromycin base (1 g/day)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (2 g/day)
Number of subjects: 1244
Study: 773506

Group type: EXPERIMENTAL
Intervention: Amitriptyline (75‐225 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flupenthixol (1‐5‐4‐5 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 31677259

Group type: EXPERIMENTAL
Intervention: Primary tumor resection
Number of subjects: 2694
Study: 29153759

Group type: EXPERIMENTAL
Intervention: Knowledgeable Together (higher dyad knowledge, less incongruence; N = 85, 75%)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Knowledge Gap (lower dyad knowledge, greater incongruence; N = 29, 25%)
Number of subjects: 114
Study: 27775503

Group type: EXPERIMENTAL
Intervention: Short-term storage group (mean storage duration 13.0 days)
Number of subjects: 20858

Group type: COMPARATOR
Intervention: Long-term storage group (mean storage duration 23.6 days)
Number of subjects: 20858

Group type: EXPERIMENTAL
Intervention: Any blood type analysis (short-term storage)
Number of subjects: 20858

Group type: COMPARATOR
Intervention: Any blood type analysis (long-term storage)
Number of subjects: 20858
Study: 24178969

Group type: EXPERIMENTAL
Intervention: Insulin-sensitization therapy
Number of subjects: 1799

Group type: COMPARATOR
Intervention: Insulin-provision therapy
Number of subjects: 1799
Study: 22220945

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg DMT
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 51
Study: 20171326

Group type: EXPERIMENTAL
Intervention: Analytical rumination
Number of subjects: 77

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 77
Study: 17378781

Group type: EXPERIMENTAL
Intervention: Pre‐emptive stellate ganglion block (SGB) using 10 ml of ropivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no SGB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pre‐emptive stellate ganglion block (SGB)
Number of subjects: 100
Study: 16323385

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation combined with AChE‐I (rivastigmine) treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: AChE‐I only (control group)
Number of subjects: 13
Study: 12006327

Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg daily
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Ibandronate 2.5 mg daily
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Ibandronate 5 mg daily
Number of subjects: 182

Group type: COMPARATOR
Intervention: Alendronate (all doses)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Ibandronate (all doses)
Number of subjects: 182
Study: 10049274

Group type: EXPERIMENTAL
Intervention: Abacavir (100, 300, 600, 900, and 1,200 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Abacavir (300 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Abacavir (various doses)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Abacavir (caplet formulation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7577484

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clodronate 1500 mg
Number of subjects: 41
Study: 1971645

Group type: COMPARATOR
Intervention: Ceftazidime (C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftazidime and Gentamicin (C + G)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime and Teicoplanin (C + T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime, Gentamicin, and Teicoplanin (C + G + T)
Number of subjects: 0
Study: 6784594

Group type: EXPERIMENTAL
Intervention: Mr. 1268 (M1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: pentazocine (M2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: tramadol (M3)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mr. 1353 (M4)
Number of subjects: 9
Study: 31104285

Group type: EXPERIMENTAL
Intervention: c‐tDCS
Number of subjects: 42

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 42
Study: 28160670

Group type: EXPERIMENTAL
Intervention: Comprehensive CT scan of the abdomen/pelvis
Number of subjects: 854

Group type: COMPARATOR
Intervention: Limited screening strategy
Number of subjects: 854
Study: 25649637

Group type: EXPERIMENTAL
Intervention: lotrafilcon A (Dk, 140)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: galyfilcon A (Dk, 60)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: +6.00 D power lenses (averaged across lens materials)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: -10.00 D and -3.00 D lenses
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no lens)
Number of subjects: 29
Study: 24634622

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) therapy for 6 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (16 subjects)
Number of subjects: 22
Study: 21952002

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 30 minutes of brisk walking daily for 3 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 33
Study: 19651266

Group type: EXPERIMENTAL
Intervention: Customized exercise program for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 42
Study: 17241844

Group type: EXPERIMENTAL
Intervention: Universal placebo gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: PSS placebo gel
Number of subjects: 30
Study: 15962898

Group type: COMPARATOR
Intervention: ORS/WHO standard treatment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ORS/plantain solution (50 g of precooked plantain flour instead of glucose)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ORS/plantain solution
Number of subjects: 101
Study: 12060421

Group type: EXPERIMENTAL
Intervention: 0.12% PHMB mouthrinse (A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine rinse (C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chlorhexidine (C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Listerine (D)
Number of subjects: 16
Study: 9796961

Group type: EXPERIMENTAL
Intervention: Cremophor 30 ml/m2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cremophor 45 ml/m2 with 35 mg/m2 doxorubicin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cremophor 60 ml/m2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cremophor 45 ml/m2 and 60 ml/m2
Number of subjects: 10
Study: 7899064

Group type: EXPERIMENTAL
Intervention: Combined concurrent bronchial artery infusion (BAI) of CDDP (50 mg) and unevenly fractionated radiotherapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Evenly fractionated irradiation (radiation group)
Number of subjects: 55
Study: 1298056

Group type: EXPERIMENTAL
Intervention: Nasogastric tube (NGT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Convenience of care (NGT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Convenience of care (PEG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patient satisfaction (NGT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Patient satisfaction (PEG)
Number of subjects: 90
Study: 6150716

Group type: EXPERIMENTAL
Intervention: bezafibrate (3 X 200 mg/die)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: somatostatin infusion
Number of subjects: 10
Study: 30814568

Group type: EXPERIMENTAL
Intervention: Low 25OHD levels (measured by genetic variants)
Number of subjects: 327478

Group type: EXPERIMENTAL
Intervention: Individual 25OHD-reducing genetic variants
Number of subjects: 327478

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 327478
Study: 29609921

Group type: EXPERIMENTAL
Intervention: Simulated laughter
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Spontaneous laughter
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (non-humorous documentary)
Number of subjects: 72
Study: 26705681

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (40 mg/m², 7 doses)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Triweekly cisplatin (100 mg/m², 3 doses)
Number of subjects: 109
Study: 25263261

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inactivity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise plus CM
Number of subjects: 20

Group type: COMPARATOR
Intervention: CM-control (non-contingent incentives)
Number of subjects: 20
Study: 23393217

Group type: EXPERIMENTAL
Intervention: nurse-community health worker (CHW) team intervention
Number of subjects: 268

Group type: COMPARATOR
Intervention: usual care (wait-list control group)
Number of subjects: 268
Study: 21175437

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pool model with circadian rhythm function
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both models (AAI and Pool)
Number of subjects: 8
Study: 19450116

Group type: EXPERIMENTAL
Intervention: 12 weeks of peginterferon alfa-2b + ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24 weeks of peginterferon alfa-2b + ribavirin
Number of subjects: 0
Study: 16614779

Group type: EXPERIMENTAL
Intervention: 0.75 ml of 0.3 percent nitroglycerin ointment (2.25 mg nitroglycerin) t.i.d. intra‐anal using the cannula (Group A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.75 ml of 0.3 percent nitroglycerin ointment (2.25 mg nitroglycerin) perianally with the gloved finger (Group B)
Number of subjects: 26
Study: 12919338

Group type: EXPERIMENTAL
Intervention: Surgical interventions for epilepsy (specific interventions not detailed in the abstract)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Nonrandomized (observational) studies
Number of subjects: 535
Study: 11026212

Group type: EXPERIMENTAL
Intervention: Manipulation of certainty, view, and attention
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Manipulation of certainty, description, and time
Number of subjects: 386
Study: 9542752

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g daily) and d-alpha-tocopherol (1000 IU daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8392820

Group type: EXPERIMENTAL
Intervention: Active medication (0.3 mg atropine sulfate and 60 mg pseudoephedrine)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (inert capsules)
Number of subjects: 43
Study: 3556983

Group type: EXPERIMENTAL
Intervention: Intravenous cisapride (8 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29975573

Group type: EXPERIMENTAL
Intervention: Balance-training protocol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Strength-training protocol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 26807898

Group type: EXPERIMENTAL
Intervention: Lamellar corneal transplantation (LCT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9
Study: 25529948

Group type: EXPERIMENTAL
Intervention: 3D‐EAUS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine examinations (digital examination and probe)
Number of subjects: 100
Study: 22815422

Group type: EXPERIMENTAL
Intervention: Oral ivabradine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral metoprolol
Number of subjects: 100